Protara Therapeutics Inc TARA.OQ TARA.O is expected to show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Protara Therapeutics Inc is for a loss of 40 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Protara Therapeutics Inc is $22.50, about 86.2% above its last closing price of $3.10
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.40 | -0.45 | -0.29 | Beat | 35.8 |
Dec. 31 2025 | -0.56 | -0.56 | -0.49 | Beat | 13.3 |
Sep. 30 2024 | -0.52 | -0.52 | -0.50 | Beat | 3.8 |
Jun. 30 2024 | -0.96 | -0.80 | -0.45 | Beat | 43.8 |
Mar. 31 2024 | -0.86 | -0.92 | -0.97 | Missed | -5.4 |
Dec. 31 2023 | -0.92 | -0.90 | Beat | 1.9 | |
Sep. 30 2023 | -1.04 | -0.98 | -0.87 | Beat | 11.2 |
Jun. 30 2023 | -0.88 | -0.87 | -1.00 | Missed | -14.3 |
This summary was machine generated August 1 at 14:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)